Ablynx N.v.

Aicuris Gmbh + Co. Kg.

Bayer Schering Pharma Ag

Janssen R&d Ireland

Bayer Aktiengesellschaft

Novartis Ag

Sanofi

Akzo Nobel N.v.

Bayer Healthcare Aktiengesellschaft

Judith Baumeister

Kerstin Henninger

Marie-Ange Buyse

Veerle Snoeck

Carlo Boutton

Tobias Wunberg

Mario Jeske

Bruno Dombrecht

Holger Zimmermann

Stephanie Staelens

Soren Steffensen

Dieter Lang

Rolf Grosser

Guy Hewlett

Susanne Nikolic

Jörg Keldenich

Peter Nell

Guy Hermans

Gerald Beste

Peter Schotte

Cedric Jozef Neotere Ververken

Ulrich Betz

Alexander Szyroki

Tinneke Denayer

Marie-Paule Lucienne Armanda Bouche

Frank Suessmeier

Tim Hugo Maria Jonckers

Rudolf Schohe-Loop

Thomas Lampe

Gerald Kleymann

Frank Süβmeier

Karen Cromie

Steven John Charlton

Zarin Brown

Michelle Bradley

Gerben Albert Van 't Klooster

Marie-Paule Bouche

Martin Hendrix

Udo Schneider

Joerg Keldenich

Olaf Weber

Wolfgang Bender

Geerwin Yvonne Paul Haché

Tse-I Lin

Peter Eckenberg

Jürgen Reefschläger

Wim Bert Griet Schepens

Axel Jensen

Gabriele Handke

Gino Anselmus Van Heeke

Jennifer Chiyomi Sasaki

Beate Sabine Hallenberger

Rüdiger Fischer

Stefaan Julien Last

Herman Augustinus De Kock

Gino Van Heeke

J&ouml;rg Keldenich

Thomas Krämer

Frank Süssmeier

R&uuml;diger Fischer

Inge Dierynck

Paul Jozef Gabriel Maria Boonants

Heinz-J&uuml;rgen Thiel

Robert Stark

Matthias K&ouml;nig

Juergen Reefschlaeger

Frank Süßmeier

Lin Tse-I

Kjell Mortier

Sofie Poelmans

Lieselot Bontinck

Marie-Paule Lucienne Bouche

This invention provides, and in certain specific but non-limiting aspects relates to: assays that can be used to predict whether a given ISV will be subject to protein interference as described herein and/or give rise to an (aspecific) signal in such an assay (such as for example in an ADA immunoassay). Such predictive assays could for example be used to test whether a given ISV could have a tendency to give rise to such protein interference and/or such a signal; to select ISV's that are not or less prone to such protein interference or to giving such a signal; as an assay or test that can be used to test whether certain modification(s) to an ISV will (fully or partially) reduce its tendency to give rise to such interference or such a signal; and/or as an assay or test that can be used to guide modification or improvement of an ISV so as to reduce its tendency to give rise to such protein interference or signal;—methods for modifying and/or improving ISV's to as to remove or reduce their tendency to give rise to such protein interference or such a signal;—modifications that can be introduced into an ISV that remove or reduce its tendency to give rise to such protein interference or such a signal; ISV's that have been specifically selected (for example, using the assay(s) described herein) to have no or low(er)/reduced tendency to give rise to such protein interference or such a signal; modified and/or improved ISV's that have no or a low(er)/reduced tendency to give rise to such protein interference or such a signal.

Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains

This invention provides, and in certain specific but non-limiting aspects relates to: assays that can be used to predict whether a given ISV will be subject to protein interference as described herein and/or give rise to an (aspecific) signal in such an assay (such as for example in an ADA immunoassay). Such predictive assays could for example be used to test whether a given ISV could have a tendency to give rise to such protein interference and/or such a signal; to select ISV's that are not or less prone to such protein interference or to giving such a signal; as an assay or test that can be used to test whether certain modification(s) to an ISV will (fully or partially) reduce its tendency to give rise to such interference or such a signal; and/or as an assay or test that can be used to guide modification or improvement of an ISV so as to reduce its tendency to give rise to such protein interference or signal; methods for modifying and/or improving ISV's to as to remove or reduce their tendency to give rise to such protein interference or such a signal; modifications that can be introduced into an ISV that remove or reduce its tendency to give rise to such protein interference or such a signal; ISV's that have been specifically selected (for example, using the assay(s) described herein) to have no or low(er)/reduced tendency to give rise to such protein interference or such a signal; modified and/or improved ISV's that have no or a low(er)/reduced tendency to give rise to such protein interference or such a signal.

The present invention relates to polypeptides directed against or specifically binding to C&#x2014;X&#x2014;C Motif chemokine receptor 2 (CXCR2) and in particular to polypeptides capable of modulating signal transduction from CXCR2. The invention also relates to nucleic acids, vectors and host cells capable of expressing the polypeptides of the invention, pharmaceutical compositions comprising the polypeptides and uses of said polypeptides and compositions for treatment of diseases involving aberrant functioning of CXCR2.

Chemokine receptor binding polypeptides

This invention provides, and in certain specific but non-limiting aspects relates to: assays that can be used to predict whether a given ISV will be subject to protein interference and/or give rise to an (aspecific) signal in such an assay (such as in an ADA immunoassay; methods for modifying and/or improving ISV's to as to remove or reduce their tendency to give rise to such protein interference or such a signal; modifications that can be introduced into an ISV that remove or reduce its tendency to give rise to such protein interference or such a signal; ISV's that have been specifically selected (for example, using the assay(s) described herein) to have no or low(er)/reduced tendency to give rise to such protein interference or such a signal; modified and/or improved ISV's that have no or a low(er)/reduced tendency to give rise to such protein interference or such a signal.

Serum albumin binding proteins containing immunoglobulin single variable domains

This invention provides, and in certain specific but non-limiting aspects relates to: &#x2014;assays that can be used to predict whether a given ISV will be subject to protein interference as described herein and/or give rise to an (aspecific) signal in such an assay (such as for example in an ADA immunoassay). Such predictive assays could for example be used to test whether a given ISV could have a tendency to give rise to such protein interference and/or such a signal; to select ISV's that are not or less prone to such protein interference or to giving such a signal; as an assay or test that can be used to test whether certain modification(s) to an ISV will (fully or partially) reduce its tendency to give rise to such interference or such a signal; and/or as an assay or test that can be used to guide modification or improvement of an ISV so as to reduce its tendency to give rise to such protein interference or signal; &#x2014;methods for modifying and/or improving ISV's to as to remove or reduce their tendency to give rise to such protein interference or such a signal; &#x2014;modifications that can be introduced into an ISV that remove or reduce its tendency to give rise to such protein interference or such a signal; &#x2014;ISV's that have been specifically selected (for example, using the assay(s) described herein) to have no or low(er)/reduced tendency to give rise to such protein interference or such a signal; &#x2014;modified and/or improved ISV's that have no or a low(er)/reduced tendency to give rise to such protein interference or such a signal.

Described herein are methods, assays and techniques for detecting and/or measuring anti-drug antibodies that bind to a protein, polypeptide or other compound or molecule that comprises at least one immunoglobulin variable domain with an exposed C-terminal region.

Methods for detecting and/or measuring anti-drug antibodies, in particular treatment-emergent anti-drug antibodies

This invention provides, and in certain specific but non-limiting aspects relates to: assays that can be used to predict whether a given ISV will be subject to protein interference as described herein and/or give rise to an (aspecific) signal in such an assay (such as for example in an ADA immunoassay). Such predictive assays could for example be used to test whether a given ISV could have a tendency to give rise to such protein interference and/or such a signal; to select ISV's that are not or less prone to such protein interference or to giving such a signal; as an assay or test that can be used to test whether certain modification(s) to an ISV will (fully or partially) reduce its tendency to give rise to such interference or such a signal; and/or as an assay or test that can be used to guide modification or improvement of an ISV so as to reduce its tendency to give rise to such protein interference or signal; &#x2014;methods for modifying and/or improving ISV's to as to remove or reduce their tendency to give rise to such protein interference or such a signal; &#x2014;modifications that can be introduced into an ISV that remove or reduce its tendency to give rise to such protein interference or such a signal; ISV's that have been specifically selected (for example, using the assay(s) described herein) to have no or low(er)/reduced tendency to give rise to such protein interference or such a signal; modified and/or improved ISV's that have no or a low(er)/reduced tendency to give rise to such protein interference or such a signal.

The present invention relates to polypeptides directed against or specifically binding to chemokine receptor CXCR2 and in particular to polypeptides capable of modulating signal transduction from CXCR2. The invention also relates to nucleic acids, vectors and host cells capable of expressing the polypeptides of the invention, pharmaceutical compositions comprising the polypeptides and uses of said polypeptides and compositions for treatment of diseases involving aberrant functioning of CXCR2.

The present invention relates to polypeptides directed against or specifically binding to CXC chemokine receptor 2 ('CXCR2') and in particular to polypeptides capable of modulating signal transduction from CXCR2. The invention also relates to nucleic acids, vectors and host cells capable of expressing the polypeptides of the invention, pharmaceutical compositions comprising the polypeptides and uses of said polypeptides and compositions for treatment of diseases involving aberrant functioning of CXCR2.

The present invention relates to compounds of formula (I) that have CYP450 inhibiting properties and are useful as boosting agents when used with HIV treatments. These compounds are represented by formula including the salts and stereoisomeric forms thereof, wherein Ris 5-thiazolyl or 3-pyridinyl; Ris iso-butyl, 2,2-dimethylpropyl; 2-hydroxy-2-methyl-propyl or cyclohexylmethyl; Ris phenyl optionally substituted with one or more halogens, trifluoromethyl, C-alkyl or C-alkoxy wherein optionally two of said alkoxy groups are be linked to each other to form a 5 or 6-membered ring; heteroaryl; Ccycloalkyl optionally substituted with one or more halogens; Calkyl optionally substituted with heteroaryl; &#x2014;O&#x2014;CH&#x2014; (heteroaryl). As boosting agents they are able to increase at least one of the pharmacokinetic variables of certain drugs when co-administered, or improve the bioavailability of certain drugs. Methods for the preparation of the compounds of the invention and pharmaceutical compositions comprising these compounds are also provided.

Amide compounds as boosters of antivirals

The invention relates to substituted dihydroquinazolines and to processes for their preparation and also to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular for use as antiviral agents, in particular against cytomegalo viruses.

Substituted dihydroquinazolines

The present invention relates to compounds that have CYP450 inhibiting properties and are therefore useful as boosters of certain drugs, i.e. they are able to increase at least one of the pharmacokinetic variables of certain drugs when co-administered. The invention further provides the use of said compounds as improvers of the bioavailability of certain drugs. Methods for the preparation of the compounds of the invention and pharmaceutical compositions are also provided.

The invention relates to heterocyclyl-substituted dihydroquinazolines of formula (I), to processes for their preparation, to medicaments containing them, and to methods for the treatment and/or prophylaxis of diseases, in particular, for use as anti-viral agents, in particular, against cytomegaloviruses.

Heterocyclyl-substituted dihydroquinazolines and their use as antiviral agents

The invention relates to substituted dihydroquinazolines and to a method for the production thereof, the use thereof for treating and/or preventing diseases and for producing drugs for treating and/or preventing diseases, in particular for the use of the inventive dihydroquinazolines in the form of antiviral agents, in particular against cytomegaloviruses.

Substituted dihydroquinazolines II

The present invention relates to 2-(substituted-amino)-benzothiazole sulfonamide compounds and derivatives, their use as protease inhibitors, in particular as broad-spectrum HIV protease inhibitors, processes for their preparation as well as pharmaceutical compositions and diagnostic kits comprising them. The present invention also concerns combinations of the present 2-(substituted-amino)-benzothiazole sulfonamide compounds and derivatives with another anti-retroviral agent. It further relates to their use in assays as reference compounds or as reagents.

2-(substituted-amino)-benzothiazole sulfonamide HIV protease inhibitors

Growing community of inventors

Mechelen, Belgium

Judith Baumeister